Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|July 20, 2024
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, et al.
American Journal of Respiratory Cell and Molecular Biology|May 31, 2014
Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosisYang Sun, Dana Gallacchi, Erik Y Zhang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2023
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutionsThomas J Herzog, Shaun A Wahab, Mansoor R Mirza, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2011
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complexJune Goto, Delia M Talos, Peter Klein, et al.
Molecular Cancer Research : MCR|December 4, 2013
Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamideAndrey A Parkhitko, Carmen Priolo, Jonathan L Coloff, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Advances in Therapy|May 20, 2026
Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety StudyMaurice J D L van der Vorst, Constanza Maximiano Alonso, Tirza Areli Calderón Boyle, et al.
Clinical Therapeutics|February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid TumorsGerald Falchook, Amita Patnaik, Debra L Richardson, et al.
Plos Genetics|August 6, 2016
Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma DevelopmentKrinio Giannikou, Izabela A Malinowska, Trevor J Pugh, et al.
Gynecologic Oncology|March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safetyUrsula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Pageof 5